Navigation Links
Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers
Date:1/8/2008

There is a broad variation in the risk of developing breast cancer among people who carry the BRCA1 and BRCA2 gene mutation, according to a study in the January 9/16 issue of JAMA.

BRCA1 and BRCA2 are gene mutations that predispose carriers to breast cancer. The magnitude of the risk of breast cancer in BRCA1 and BRCA2 carriers is critical for guiding decisions concerning cancer prevention options. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but relatively little attention has been paid to the degree to which the risk may vary among carriers, according to background information in the article.

Colin B. Begg, Ph.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted an investigation to determine the extent to which risks of BRCA1 and BRCA2 carriers vary with respect to observable and unobservable characteristics. Participants in the Womens Environmental Cancer and Radiation Epidemiology (WECARE) Study, who were previously diagnosed with unilateral breast cancer (affecting only one side) or contralateral breast cancer (affecting the opposite side of an initial breast cancer), were genotyped for mutations in BRCA1 and BRCA2. All participants had their initial breast cancer diagnosed during the period from January 1985 through December 2000, before the age of 55.

Among the 1,394 participants with unilateral breast cancer, 73 (5.2 percent) were identified as carriers of deleterious mutations (42 with BRCA1 and 31 with BRCA2), the authors report. Among the 704 participants with contralateral breast cancer, 108 (15.3 percent) were identified as carriers of deleterious mutations (67 with BRCA1 and 41 with BRCA2).

Among relatives of BRCA1 and BRCA2 carriers, risk was significantly associated with a younger age at diagnosis in the proband (the family member through whom a familys medical history comes to light). There was a trend toward higher risk for relatives of participants with contralateral breast cancer vs. unilateral breast cancer participants. In addition, there were significant differences in risk between carrier families after adjusting for these observed characteristics, the authors write.

Population-based screening for BRCA1 and BRCA2 mutations is not recommended at this time. But the authors point out that in the future, as technology advances and genotyping costs are reduced, widespread genetic screening for important risk factors for breast cancer and other diseases may become routine and is likely to serve as the foundation for tailored risk reduction interventions.

For this reason, accurate estimation of the risks conferred in the population and identification of important sources of variation in these risks constitute important scientific goals with significant implications for the clinical management of female carriers of BRCA1 and BRCA2 mutations, the authors conclude.


'/>"/>

Contact: Jeanne D'Agostino
646-227-3573
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. BRCA Mutations Dont Raise Breast Cancer Risk Equally
2. American women are more likely to choose overly aggressive treatments for breast cancer
3. Breast-Feeding Seems to Protect Against Some Allergies
4. Breast Is Best for Reducing Stress
5. Localized Breast Cancer Cells Have Potential to Spread
6. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
7. ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants
8. Breast Cancer Gene Might Extend Ovarian Cancer Survival
9. Bevacizumab found to improve survival for patients with advanced breast cancer
10. Class of Chemotherapy Drugs Helps Certain Breast Cancer Patients
11. Chemotherapy and tamoxifen reduce risk of second breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Atlanta, Georgia (PRWEB) , ... December 06, 2016 ... ... 11th consecutive year to "Training" magazine’s 2017 Training Top 125 for their industry ... goals. This prestigious, annual award recognizes USA as among the global elite in ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD , ... arrival of the newest Sciton laser in January 2017. The Halo is the ... and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... leading global lifestyle design firm kathy ireland® Worldwide for five additional years, announced ... entered into an exclusive licensing agreement three years ago to design and develop ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, ... Companies) - Global Forecasts to 2021" report to their offering. ... , , ... reach USD 730.7 Million in 2021 from USD 574.8 Million in ...
(Date:12/5/2016)...  Sharn Anesthesia Inc. announced today that it has ... for Salter Labs.  The company also received the 2015 ... outstanding sales performance. Salter Labs is a ... including the market gold standard ECO 2 sampling ... the Parker Flex-Tip® Endotracheal Tube, which is a leading ...
(Date:12/5/2016)... and PUNE, India , December ... report by Allied Market Research, titled, "Global Cancer Biomarkers Market ... revenue of cancer biomarkers market is projected to reach $15,737 ... CAGR of 13.3% from 2016 to 2022. Omic technologies segment ... 2015 and is expected to maintain its dominance during the ...
Breaking Medicine Technology: